Park Ji-Hye, Yoo Chungkwon, Kim Yong Yeon
Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1871-7. doi: 10.1167/iovs.15-19003.
To investigate the efficacy of lovastatin as an antifibrotic agent after glaucoma filtration surgery (GFS) in a rabbit model.
Thirty New Zealand white rabbits underwent GFS on the right eye. The rabbits were randomly assigned to one of three groups: (1) the mitomycin-C (MMC) group, which received 0.2 mg/mL MMC-soaked Weck-Cel under the conjunctival flap; (2) the control group, which received postoperative subconjunctival injections with 0.1 mL balanced salt solution (BSS); and (3) the lovastatin group, which received postoperative subconjunctival injection with 0.1 mL lovastatin (10 μM). Intraocular pressure (IOP), bleb survival, and bleb morphology were examined until blebs showed evidence of failure. Three rabbits in each group were killed on postoperative day (POD) 5, and analyzed for histology and immunohistochemistry.
Lovastatin significantly improved bleb survival compared with that in the control group (P = 0.002); however, no significant difference in bleb survival was observed between the MMC and lovastatin groups (P = 0.097). The lovastatin group showed significantly larger and higher blebs than did the control group. Further, the IOPs of the lovastatin and MMC groups were significantly lower than that of the control group (8.0 ± 1.4 mm Hg, 7.9 ± 3.2 mm Hg, and 11.1 ± 2.9 mm Hg, respectively; P = 0.016) on POD 5. Histologic analyses revealed decreased inflammatory response and reduced fibrosis in the lovastatin group than in the control group.
Postoperative injection of lovastatin improved bleb survival in the rabbit model of GFS. Therefore, lovastatin may have potential as a novel wound-modulating agent after GFS.
在兔模型中研究洛伐他汀作为青光眼滤过手术后抗纤维化药物的疗效。
30只新西兰白兔右眼接受青光眼滤过手术。将兔子随机分为三组之一：（1）丝裂霉素C（MMC）组，在结膜瓣下接受0.2 mg/mL MMC浸湿的Weck-Cel；（2）对照组，术后结膜下注射0.1 mL平衡盐溶液（BSS）；（3）洛伐他汀组，术后结膜下注射0.1 mL洛伐他汀（10 μM）。检查眼压（IOP）、滤过泡存活情况和滤过泡形态，直至滤过泡出现失败迹象。每组3只兔子在术后第5天处死，进行组织学和免疫组织化学分析。
与对照组相比，洛伐他汀显著提高了滤过泡存活率（P = 0.002）；然而，MMC组和洛伐他汀组之间在滤过泡存活率上未观察到显著差异（P = 0.097）。洛伐他汀组的滤过泡比对照组明显更大更高。此外，术后第5天，洛伐他汀组和MMC组的眼压显著低于对照组（分别为8.0±1.4 mmHg、7.9±3.2 mmHg和11.1±2.9 mmHg；P = 0.016）。组织学分析显示，与对照组相比，洛伐他汀组的炎症反应减少，纤维化减轻。
青光眼滤过手术兔模型中，术后注射洛伐他汀可提高滤过泡存活率。因此，洛伐他汀可能有潜力作为青光眼滤过手术后一种新型的伤口调节药物。
